Alector (ALEC) Q3 2026 Earnings
Quarter includes recognition of the remaining deferred revenue under the GSK Collaboration and License Agreement following GSK's July 6, 2026 termination notice, driving collaboration revenue of $162.9 million (deferred revenue balance of $171,221 thousand at December 31, 2025 reduced to zero)
How Did ALEC Stock React to Q3 2026 Earnings?
Did ALEC Beat Earnings? Q3 2026 Results
Yes. Alector reported Q3 2026 earnings of $1.11 a share on Nov 5, 2026, beating the $0.06 consensus estimate by 1,690.3%. Revenue was $162.9M against a $29.0M estimate.
Alector, Inc. delivered a dramatic earnings beat in Q3 2026, extending its streak of beating consensus EPS estimates to seven consecutive quarters, as the neuroscience company reported GAAP EPS of $1.11 against a consensus of $0.06, a beat of 1690.32%, while revenue of $162.87 million cleared the $28.98 million estimate by 462.06% and surged 4895.9% year over year. The headline figures were driven almost entirely by a non-cash accounting event: GSK's July 6, 2026 termination notice on its Collaboration and License Agreement extinguished Alector's remaining performance obligations, triggering recognition of the full deferred revenue balance, which fell to zero from $171.22 million at year-end 2025, and pushing collaboration revenue to $162.87 million from $3.30 million a year earlier. Net income reached $124.60 million, compared with a net loss of $34.67 million in the prior-year period. Looking ahead, management expects combined resources, including a $100 million Genentech upfront payment and roughly $75 million in October offering proceeds, to fund operations into the second half of 2029, with first-in-human studies for lead program AL137 targeted no later than April 2027.
- Recognition of remaining deferred revenue from the GSK collaboration after GSK's July 6, 2026 termination notice drove collaboration revenue to $162.9 million
- R&D expenses rose on option and license fees paid under the Spur Agreement, partially offset by the wind-down of the latozinemab and nivisnebart programs
- G&A expenses fell on lower personnel-related costs from reductions in force
“Since our last quarterly update, we exclusively licensed AL050 to Genentech, strengthened our balance sheet, and moved our wholly owned programs closer to the clinic.”
Alector CEO, on the earnings call
What Is Alector's Outlook?
Management expects cash, cash equivalents and investments of $138.7 million, together with the $100 million Genentech upfront payment and net proceeds from the roughly $75 million October 2026 offering, to fund operations into the second half of 2029. Planned milestones: - AL137 first-in-human subcutaneous dosing in healthy volunteers in Australia no later than April 2027 - U.S. IND submission for AL137 in Q2 2027 to enable Phase 1b studies in AD patients - AL164 and AL062 first-in-human studies in Q2 2028 - ADP065 advancing toward lead selection
ALEC YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $162.9M | $3.3M | +4,895.9% |
| Operating Income | $123.8M | $23.4M | +429.3% |
| Net Income | $124.6M | $22.3M | +459.4% |
ALEC Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.